View printer-friendly version |
Charles River Laboratories Awarded Five-Year, $95.7 Million Contract by the National Institute of Allergy and Infectious Diseases
The contract was awarded on
Scope of Contracted Services
Charles River’s Insourcing Solutions business will manage approximately 200 on-site, Charles River personnel to support the NIAID contract, ranging from program management, training, quality control, animal husbandry, veterinary, technical, research, and administrative support staff. The staff will provide a wide range of technical and support services required for biomedical research involving multiple scientific disciplines. The scope of the contracted services includes veterinary medical care, research model husbandry, technical support, data management, routine maintenance, sanitation, transportation, logistics, and administrative support. The services will be provided on location at various NIAID and other government facilities. Charles River’s Insourcing Solutions business offers recruiting, training, staffing and vivarium management services to academic, government and biopharmaceutical clients.
This project will be 100% funded with federal funds from the
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as
“anticipate,” “believe,” “expect,” “intend,” “will,” “may,” “estimate,”
“plan,” “outlook,” and “project,” and other similar expressions that
predict or indicate future events or trends or that are not statements
of historical matters. Forward looking statements include statements in
this press release regarding the anticipated revenue and duration of the
NIAID contract, and the services performed under this contract, and the
impact on Charles River’s 2018 financial results. Forward-looking
statements are based on Charles River’s current expectations and
beliefs, and involve a number of risks and uncertainties that are
difficult to predict and that could cause actual results to differ
materially from those stated or implied by the forward-looking
statements. A further description of these risks, uncertainties, and
other matters can be found in the Risk Factors detailed in Charles
River's Annual Report on Form 10-K as filed on
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005147/en/
Source:
Charles River Laboratories International, Inc.
Investor Contacts:
Todd
Spencer, 781-222-6455
Corporate Vice President, Investor Relations
todd.spencer@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com